{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:48:48Z","timestamp":1789019328833,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11883-025-01299-7","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T05:59:50Z","timestamp":1745992790000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Oral PCSK9 Inhibitors: Will They Work?"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6441-3339","authenticated-orcid":false,"given":"Lale","family":"Tokg\u00f6zo\u011flu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2948-6257","authenticated-orcid":false,"given":"Angela","family":"Pirillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7593-2094","authenticated-orcid":false,"given":"Alberico L.","family":"Catapano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"issue":"32","key":"1299_CR1","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society consensus panel. Eur Heart J. 2017;38(32):2459\u201372. https:\/\/doi.org\/10.1093\/eurheartj\/ehx144.","journal-title":"Eur Heart J"},{"issue":"24","key":"1299_CR2","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","volume":"41","author":"J Boren","year":"2020","unstructured":"Boren J, Chapman MJ, Krauss RM, Packard CJ, Bentzon JF, Binder CJ, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European atherosclerosis society consensus panel. Eur Heart J. 2020;41(24):2313\u201330. https:\/\/doi.org\/10.1093\/eurheartj\/ehz962.","journal-title":"Eur Heart J"},{"issue":"1","key":"1299_CR3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455.","journal-title":"Eur Heart J"},{"issue":"10","key":"1299_CR4","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41569-021-00541-4","volume":"18","author":"A Pirillo","year":"2021","unstructured":"Pirillo A, Casula M, Olmastroni E, Norata GD, Catapano AL. Global epidemiology of dyslipidaemias. Nature reviews. Cardiology. 2021;18(10):689\u2013700. https:\/\/doi.org\/10.1038\/s41569-021-00541-4.","journal-title":"Cardiology"},{"key":"1299_CR5","doi-asserted-by":"publisher","first-page":"100624","DOI":"10.1016\/j.lanepe.2023.100624","volume":"29","author":"KK Ray","year":"2023","unstructured":"Ray KK, Haq I, Bilitou A, Manu MC, Burden A, Aguiar C, et al. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study. Lancet Reg Health Eur. 2023;29:100624. https:\/\/doi.org\/10.1016\/j.lanepe.2023.100624.","journal-title":"Lancet Reg Health Eur"},{"issue":"15","key":"1299_CR6","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1093\/eurjpc\/zwae199","volume":"31","author":"KK Ray","year":"2024","unstructured":"Ray KK, Aguiar C, Arca M, Connolly DL, Eriksson M, Ferrieres J, et al. Use of combination therapy is associated with improved LDL cholesterol management: 1-year follow-up results from the European observational SANTORINI study. Eur J Prev Cardiol. 2024;31(15):1792\u2013803. https:\/\/doi.org\/10.1093\/eurjpc\/zwae199.","journal-title":"Eur J Prev Cardiol"},{"issue":"25","key":"1299_CR7","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to Statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387\u201397. https:\/\/doi.org\/10.1056\/NEJMoa1410489.","journal-title":"N Engl J Med"},{"issue":"15","key":"1299_CR8","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","volume":"388","author":"SE Nissen","year":"2023","unstructured":"Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, et al. Bempedoic acid and cardiovascular outcomes in Statin-Intolerant patients. N Engl J Med. 2023;388(15):1353\u201364. https:\/\/doi.org\/10.1056\/NEJMoa2215024.","journal-title":"N Engl J Med"},{"issue":"18","key":"1299_CR9","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1615664.","journal-title":"N Engl J Med"},{"issue":"22","key":"1299_CR10","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097\u2013107. https:\/\/doi.org\/10.1056\/NEJMoa1801174.","journal-title":"N Engl J Med"},{"issue":"6","key":"1299_CR11","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/s44161-022-00085-x","volume":"1","author":"P Libby","year":"2022","unstructured":"Libby P, Tokgozoglu L. Chasing LDL cholesterol to the bottom - PCSK9 in perspective. Nat Cardiovasc Res. 2022;1(6):554\u201361. https:\/\/doi.org\/10.1038\/s44161-022-00085-x.","journal-title":"Nat Cardiovasc Res"},{"issue":"20","key":"1299_CR12","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1016\/j.jacc.2024.09.012","volume":"84","author":"Y Sun","year":"2024","unstructured":"Sun Y, Lv Q, Guo Y, Wang Z, Huang R, Gao X, et al. Recaticimab as Add-On therapy to Statins for nonfamilial hypercholesterolemia: the randomized, phase 3 REMAIN-2 trial. J Am Coll Cardiol. 2024;84(20):2037\u201347. https:\/\/doi.org\/10.1016\/j.jacc.2024.09.012.","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"1299_CR13","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1016\/j.jacc.2024.07.035","volume":"84","author":"M Xu","year":"2024","unstructured":"Xu M, Wang Z, Zhang Y, Liu Y, Huang R, Han X, et al. Recaticimab monotherapy for nonfamilial hypercholesterolemia and mixed hyperlipemia: the phase 3 REMAIN-1 randomized trial. J Am Coll Cardiol. 2024;84(20):2026\u201336. https:\/\/doi.org\/10.1016\/j.jacc.2024.07.035.","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"1299_CR14","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1912387.","journal-title":"N Engl J Med"},{"issue":"16","key":"1299_CR15","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","volume":"382","author":"FJ Raal","year":"2020","unstructured":"Raal FJ, Kallend D, Ray KK, Turner T, Koenig W, Wright RS, et al. Inclisiran for the treatment of heterozygous Familial hypercholesterolemia. N Engl J Med. 2020;382(16):1520\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1913805.","journal-title":"N Engl J Med"},{"issue":"40","key":"1299_CR16","doi-asserted-by":"publisher","first-page":"4272","DOI":"10.1093\/eurheartj\/ehad596","volume":"44","author":"F Raal","year":"2023","unstructured":"Raal F, Fourie N, Scott R, Blom D, De Vries Basson M, Kayikcioglu M, et al. Long-term efficacy and safety of Lerodalcibep in heterozygous Familial hypercholesterolaemia: the LIBerate-HeFH trial. Eur Heart J. 2023;44(40):4272\u201380. https:\/\/doi.org\/10.1093\/eurheartj\/ehad596.","journal-title":"Eur Heart J"},{"issue":"9","key":"1299_CR17","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1001\/jamacardio.2024.1659","volume":"9","author":"EQ Klug","year":"2024","unstructured":"Klug EQ, Llerena S, Burgess LJ, Fourie N, Scott R, Vest J, et al. Efficacy and safety of Lerodalcibep in patients with or at high risk of cardiovascular disease: A randomized clinical trial. JAMA Cardiol. 2024;9(9):800\u20137. https:\/\/doi.org\/10.1001\/jamacardio.2024.1659.","journal-title":"JAMA Cardiol"},{"issue":"9","key":"1299_CR18","doi-asserted-by":"publisher","first-page":"101726","DOI":"10.1016\/j.xcrm.2024.101726","volume":"5","author":"A Sahebkar","year":"2024","unstructured":"Sahebkar A, Banach M. Transforming hypercholesterolemia management: spotlight on PCSK9 peptide vaccines. Cell Rep Med. 2024;5(9):101726. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101726.","journal-title":"Cell Rep Med"},{"issue":"2","key":"1299_CR19","doi-asserted-by":"publisher","first-page":"100497","DOI":"10.1016\/j.jlr.2024.100497","volume":"65","author":"MM Vroom","year":"2024","unstructured":"Vroom MM, Lu H, Lewis M, Thibodeaux BA, Brooks JK, Longo MS, et al. VXX-401, a novel anti-PCSK9 vaccine, reduces LDL-C in cynomolgus monkeys. J Lipid Res. 2024;65(2):100497. https:\/\/doi.org\/10.1016\/j.jlr.2024.100497.","journal-title":"J Lipid Res"},{"issue":"2","key":"1299_CR20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1093\/ehjcvp\/pvad103","volume":"10","author":"T Horie","year":"2024","unstructured":"Horie T, Ono K. VERVE-101: a promising CRISPR-based gene editing therapy that reduces LDL-C and PCSK9 levels in HeFH patients. Eur Heart J Cardiovasc Pharmacother. 2024;10(2):89\u201390. https:\/\/doi.org\/10.1093\/ehjcvp\/pvad103.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"2","key":"1299_CR21","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1161\/CIRCULATIONAHA.122.063372","volume":"148","author":"DG Johns","year":"2023","unstructured":"Johns DG, Campeau LC, Banka P, Bautmans A, Bueters T, Bianchi E, et al. Orally bioavailable macrocyclic peptide that inhibits binding of PCSK9 to the low density lipoprotein receptor. Circulation. 2023;148(2):144\u201358. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.063372.","journal-title":"Circulation"},{"issue":"10","key":"1299_CR22","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/d41573-023-00152-3","volume":"22","author":"K Kingwell","year":"2023","unstructured":"Kingwell K. Macrocycle drugs serve up new opportunities. Nature reviews. Drug Discovery. 2023;22(10):771\u20133. https:\/\/doi.org\/10.1038\/d41573-023-00152-3.","journal-title":"Drug Discovery"},{"issue":"16","key":"1299_CR23","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.jacc.2023.02.018","volume":"81","author":"CM Ballantyne","year":"2023","unstructured":"Ballantyne CM, Banka P, Mendez G, Garcia R, Rosenstock J, Rodgers A, et al. Phase 2b randomized trial of the oral PCSK9 inhibitor MK-0616. J Am Coll Cardiol. 2023;81(16):1553\u201364. https:\/\/doi.org\/10.1016\/j.jacc.2023.02.018.","journal-title":"J Am Coll Cardiol"},{"key":"1299_CR24","unstructured":"O\u2019Mahony G. August 21,. AZD0780 - an oral PCSK9 inhibitor with a novel mode of action for the treatment of cardiovascular disease. Abstract presented at ACS 2024. Denver, Colorado (2024)."},{"key":"1299_CR25","doi-asserted-by":"publisher","unstructured":"Vega R, Garkaviy P, Kn\u00f6chel J, Barbour A, Rudvik A, Laru J, et al. AZD0780, the first oral small molecule PCSK9 inhibitor for the treatment of hypercholesterolemia: results from a randomized, single-blind, placebo-controlled phase 1 trial. Atherosclerosis. 2024;395. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2024.118514.","DOI":"10.1016\/j.atherosclerosis.2024.118514"},{"key":"1299_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2025.03.499","author":"MJ Koren","year":"2025","unstructured":"Koren MJ, Vega RB, Agrawal N, Xu Y, Barbour AM, Yu H, et al. An oral PCSK9 inhibitor for treatment of hypercholesterolemia: the PURSUIT randomized trial. J Am Coll Cardiol. 2025. https:\/\/doi.org\/10.1016\/j.jacc.2025.03.499. 31 March 2025.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1299_CR27","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S2213-8587(23)00325-X","volume":"12","author":"MJ Koren","year":"2024","unstructured":"Koren MJ, Descamps O, Hata Y, Hengeveld EM, Hovingh GK, Ikonomidis I, et al. PCSK9 Inhibition with orally administered NNC0385-0434 in hypercholesterolaemia: a randomised, double-blind, placebo-controlled and active-controlled phase 2 trial. Lancet Diabetes Endocrinol. 2024;12(3):174\u201383. https:\/\/doi.org\/10.1016\/S2213-8587(23)00325-X.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1299_CR28","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.atherosclerosis.2022.06.075","volume":"355","author":"A Hofherr","year":"2022","unstructured":"Hofherr A, Schumi J, Reki\u0107 D, Kn\u00f6chel J, Nilsson CAM, Rudvik A, et al. ETESIAN: A phase 2B study of the efficacy, safety and tolerability of AZD8233, a PCSK9-targeted antisense oligonucleotide, in patients with dyslipidemia. Atherosclerosis. 2022;355:28. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.06.075.","journal-title":"Atherosclerosis"},{"key":"1299_CR29","doi-asserted-by":"publisher","unstructured":"Gennemark P, Walter K, Clemmensen N, Rekic D, Nilsson CAM, Knochel J, et al. An oral antisense oligonucleotide for PCSK9 Inhibition. Sci Transl Med. 2021;13(593). https:\/\/doi.org\/10.1126\/scitranslmed.abe9117.","DOI":"10.1126\/scitranslmed.abe9117"},{"issue":"11","key":"1299_CR30","doi-asserted-by":"publisher","first-page":"100293","DOI":"10.1016\/j.jlr.2022.100293","volume":"63","author":"AK Suchowerska","year":"2022","unstructured":"Suchowerska AK, Stokman G, Palmer JT, Coghlan PA, Pieterman EJ, Keijzer N, et al. A novel, orally bioavailable, Small-Molecule inhibitor of PCSK9 with significant Cholesterol-Lowering properties in vivo. J Lipid Res. 2022;63(11):100293. https:\/\/doi.org\/10.1016\/j.jlr.2022.100293.","journal-title":"J Lipid Res"},{"issue":"5","key":"1299_CR31","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.cmet.2022.03.006","volume":"34","author":"J Wang","year":"2022","unstructured":"Wang J, Zhao J, Yan C, Xi C, Wu C, Zhao J, et al. Identification and evaluation of a lipid-lowering small compound in preclinical models and in a phase I trial. Cell Metab. 2022;34(5):667\u201380. https:\/\/doi.org\/10.1016\/j.cmet.2022.03.006. e6.","journal-title":"Cell Metab"},{"key":"1299_CR32","doi-asserted-by":"publisher","DOI":"10.1161\/circ.142.suppl_3.12579","author":"J Liu","year":"2020","unstructured":"Liu J, Jiang B, Zhao S, Cai S, Xiang D, Huang M, et al. Abstract 12579: CVI-LM001, a First-in-class novel oral PCSK9 modulator, lowers plasma Ldl-c and reduces Circulating PCSK9 in preclinical animal models and in hyperlipidemic human subjects. Circulation. 2020. https:\/\/doi.org\/10.1161\/circ.142.suppl_3.12579. 142(Suppl_3).","journal-title":"Circulation"},{"key":"1299_CR33","unstructured":"https:\/\/www.civibio.com\/pipeline\/civi-008\/. Accessed."},{"issue":"1","key":"1299_CR34","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/14740338.2024.2424411","volume":"24","author":"W Zeng","year":"2025","unstructured":"Zeng W, Tomlinson B. Statin alternatives for the treatment of hypercholesterolemia - a safety evaluation. Exp Opin Drug Saf. 2025;24(1):17\u201324. https:\/\/doi.org\/10.1080\/14740338.2024.2424411.","journal-title":"Exp Opin Drug Saf"},{"issue":"12","key":"1299_CR35","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1093\/ehjacc\/zuac123","volume":"11","author":"KA Krychtiuk","year":"2022","unstructured":"Krychtiuk KA, Ahrens I, Drexel H, Halvorsen S, Hassager C, Huber K, et al. Acute LDL-C reduction post ACS: strike early and strike strong: from evidence to clinical practice. A clinical consensus statement of the association for acute cardiovascular care (ACVC), in collaboration with the European association of preventive cardiology (EAPC) and the European society of cardiology working group on cardiovascular pharmacotherapy. European heart journal. Acute Cardiovasc Care. 2022;11(12):939\u201349. https:\/\/doi.org\/10.1093\/ehjacc\/zuac123.","journal-title":"Acute Cardiovasc Care"},{"issue":"15","key":"1299_CR36","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1093\/eurjpc\/zwae170","volume":"31","author":"P Gargiulo","year":"2024","unstructured":"Gargiulo P, Basile C, Galasso G, Bellino M, D\u2019Elia D, Patti G, et al. Strike early-strike strong lipid-lowering strategy with proprotein convertase subtilisin\/kexin type 9 inhibitors in acute coronary syndrome patients: real-world evidence from the AT-TARGET-IT registry. Eur J Prev Cardiol. 2024;31(15):1806\u201316. https:\/\/doi.org\/10.1093\/eurjpc\/zwae170.","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"1299_CR37","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1186\/s12872-024-04057-w","volume":"24","author":"K Hosseini","year":"2024","unstructured":"Hosseini K, Soleimani H, Maleki S, Nasrollahizadeh A, Tayebi S, Nelson J, et al. Early administration of proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2024;24(1):395. https:\/\/doi.org\/10.1186\/s12872-024-04057-w.","journal-title":"BMC Cardiovasc Disord"},{"key":"1299_CR38","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.amjcard.2023.10.043","volume":"213","author":"GB Justino","year":"2024","unstructured":"Justino GB, Justino LB, Muller ME, Rocha AV, Mazetto A, Cardoso R, et al. Early initiation of PCSK9 inhibitor therapy versus placebo in patients with acute coronary syndrome: A systematic review and Meta-Analysis. Am J Cardiol. 2024;213:110\u20138. https:\/\/doi.org\/10.1016\/j.amjcard.2023.10.043.","journal-title":"Am J Cardiol"},{"issue":"10","key":"1299_CR39","doi-asserted-by":"publisher","first-page":"e37416","DOI":"10.1097\/MD.0000000000037416","volume":"103","author":"W Shi","year":"2024","unstructured":"Shi W, Xu Y, Zhou L, Wang W, Huang W, Zhou B. In-hospital initiation of a PCSK9 inhibitor in patients with acute coronary syndrome: A systematic review and meta-analysis of randomized controlled trials. Med (Baltim). 2024;103(10):e37416. https:\/\/doi.org\/10.1097\/MD.0000000000037416.","journal-title":"Med (Baltim)"},{"issue":"34","key":"1299_CR40","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","volume":"43","author":"I Bytyci","year":"2022","unstructured":"Bytyci I, Penson PE, Mikhailidis DP, Wong ND, Hernandez AV, Sahebkar A, et al. Prevalence of Statin intolerance: a meta-analysis. Eur Heart J. 2022;43(34):3213\u201323. https:\/\/doi.org\/10.1093\/eurheartj\/ehac015.","journal-title":"Eur Heart J"},{"key":"1299_CR41","doi-asserted-by":"publisher","unstructured":"Bosco G, Di Giacomo Barbagallo F, Spampinato S, Lanzafame L, Di Pino A, Piro S, et al. Management of Statin intolerant patients in the era of novel lipid Lowering therapies: A critical approach in clinical practice. J Clin Med. 2023;12(6). https:\/\/doi.org\/10.3390\/jcm12062444.","DOI":"10.3390\/jcm12062444"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-025-01299-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-025-01299-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-025-01299-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T05:59:52Z","timestamp":1745992792000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-025-01299-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1299"],"URL":"https:\/\/doi.org\/10.1007\/s11883-025-01299-7","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]},"assertion":[{"value":"14 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Section Editors for the Topical Collection Nonstatin Drugs are Lale Tokg\u00f6zo\u011flu and Alberico L. Catapano. Please note that Section Editors, Lale Tokg\u00f6zo\u011flu and Alberico L. Catapano were not involved in the editorial process of this article as they are co-authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"LT has received has received honoraria, lecture fees, or research grants Abbott, Amarin, Amgen, Bayer, Daiichi Sankyo, Eli Lilly, Menarini, MSD, Novartis, Novo Nordisk, Sanofi, Ionis Pharmaceutical outside the submitted work. AP has nothing to disclose. ALC has received honoraria, lecture fees, or research grants from: Amarin, Amgen, Astrazeneca, Chiesi, Daiichi Sankyo, Eli Lilly, Esperion, Ionis Pharmaceutical, Medscape, Menarini, MSD, Novartis, NovoNordisk, Regeneron, Sanofi, Ultragenyx, Viatris outside the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"53"}}